ALISO VIEJO, Calif., Sept. 29 /PRNewswire-FirstCall/ -- Clarient, Inc. , a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it is scheduled to make an investor presentation at the William Blair Third Annual Emerging Growth Conference at 12:30 pm EDT on Tuesday, October 6. The conference is being held at the Waldorf Astoria in New York City.
A live webcast of the presentation will be available via a link provided at http://www.clarientinc.com/investor. An archived replay of the presentation will be available for a period of 30 days from the date of the presentation.
About Clarient
Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. Clarient’s mission is to become the leader in cancer diagnostics by collaborating with the healthcare community to translate cancer research and development into better patient care. Clarient’s principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine has created the need for a centralized resource which provides leading oncology diagnostic technologies, such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory, which provides the most advanced oncology testing and diagnostic services available. Resulting diagnostic reports and analyses are made available to customers through Clarient’s Internet-based portal, PATHSiTE(TM). Clarient also plans to develop and market new, proprietary “companion” diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. www.clarientinc.com
SOURCE Clarient, Inc.
CONTACT: Matt Clawson of Allen & Caron Inc, +1-949-474-4300,
matt@allencaron.com, for Clarient, Inc.
Web site: http://www.clarientinc.com/
